ArticleRheumatology international2025
Real-world effectiveness and safety of tocilizumab in the management of polymyalgia rheumatica: a retrospective study from the KEIO-PMR cohort.
Article in Rheumatology international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aimed to evaluate the effectiveness and safety of tocilizumab in polymyalgia rheumatica (PMR) in the real world.
methodsAll consecutive patients diagnosed with PMR who visited Keio University Hospital between May 2012 and October 2022 were retrospectively reviewed. Patients were divided into three groups: the tocilizumab group, the immunosuppressant group without biological agents, and the glucocorticoid monotherapy group. We collected clinical data including relapse, glucocorticoid doses, and adverse events during follow-up.
resultsA total of 125 patients with PMR was included in the analyses, with a mean age of 73.6 years and 83 (66.4%) female. Among them, 52 (41.6%) were in the tocilizumab group, 23 (18.4%) in the immunosuppressant group, and 50 (40.0%) in the glucocorticoid group. The glucocorticoid group showed the lowest serum C-reactive protein level at diagnosis (P = 0.046). Tocilizumab extended the time to relapse, even when given to patients with a relatively refractory disease course, although relapse assessment was not independent of C-reactive protein levels. The time to glucocorticoid discontinuation was the shortest in the tocilizumab group (P < 0.001 for induction or re-induction, P = 0.08 for maintenance). Tocilizumab use, methotrexate use and the number of relapses were identified as significant predictors of achieving glucocorticoid-free status. Adverse events were not significantly different between the three groups.
conclusionTocilizumab effectively reduced relapse rates and demonstrated glucocorticoid-sparing effects in patients with refractory PMR in the real world, with no significant safety issues. These results further support the existing evidence that tocilizumab may be a promising treatment option in real-world settings.
Indexed as
Identifiers
40856800What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.